Summary: To minimize immunological interferences on the subrenal capsule (SRC) assay, a new immunosuppressor, mizoribin (MZB : Bredinin) alone or combined with cyclosporin A (ScA) was evaluated by an experimental SRC assay system using a rat ovarian cancer tissue. Daily applications of MZB (200 mg/kg) for 7 days following the xenograf t of cancer tissue were insufficient to suppress immunological reactions of the recipient mice, and all the grafted cancer tissues were rejected. Although CsA monotreatment (60mg/kg of CsA given daily for 7 days) successfully suppressed the host immune reaction, enhanced toxicities of CsA in combination with anticancer agents caused high lethal rate of host mice during the experimental chemotherapy. Sequential use of CsA on day 0 to day 2 followed by MZB on day 3,5 and 7 brought the most favorable results with minimal host reactions and toxicities. (1980) found a strong i munosuppressive activity of MZB. In the present study, the utility of MZB was examined with respect to the SRC assay chemosensitivity test and the effect of MZB was compared to that of CsA used alone or in combination with MZB.
Materials and Methods
Female BDF1 mice were used in this experimental SRCA system. As a tumor material, a transplantable ovarian cancer tissue which had been originally induced by direct application of 7, 12 dimethylbenz (a) anthracene (DMBA) to the ovary of Wistar strain rat (Nishida et al. 1986) and maintained through 40 generations on the back of the same strain of rats (Sugiyama et al. 1986 ), was used. Under pentobarbital anesthesia, 1 mm3 of ovarian cancer tissues was implanted beneath the kidney capsule of mice following the method of Bogden et al. (1979) . and the initial tumor sizes were measured by ocular micrometer.
The mice were devided into 5 groups of 10 mice each according to the differences in the immunosuppressive treatments they received.
The first 10 mice received daily subcutaneous injection of 200 mg/kg MZB from day 0 to day 7. Group 2 mice was treated with intraperitoneal administration of 60 mg/kg CsA from the day of implantation to the 7th day. The third group received 30 mg/kg of CsA from day 0 to 7. The fourth group was administered concomitantly 30 mg/kg of CsA plus 100 mg/kg of MZB from day 0 to day 7. The fifth group received sequential administration 60 mg/kg of CsA from day 0 to day 2 followed by 200 mg /kg of MZB on day 3, 5 and 7. The effects of these immunosuppressive treatments were judged in terms of dTS (difference between the initial and final tumor size) and histological findings of the grafted tumor including mitotic index and host immune cell infiltration.
Cisplatin (8 mg/kg), doxorubicin (7 mg/kg), etoposide (17 mg/kg) and 5-f luorouracil (60 mg/kg) were tested using the mice in which the host responses were favorably controlled.
The drug sensitivities were evaluated in terms of histological change of the grafted tumor and 4TS criteria described by Maenpaa et al. (1985) . The results were interpreted as indicating tumor sensitivity if the mean tumor size had decreased by 1 omu (ocular micrometer unit: 10 omu =1 mm) or more, and tumor resistance if the mean tumor size increased by 1/3 dTS or more.
Results

Monotreatment
with MZB failed to control the immunoreaction in the host mice. All of the grafted tumors in group 1 mice were rejected or replaced by granulomatous tumor showing fibroblast proliferations and marked host immune cell inf ilatration.
While an increase in the tumor size (dTS) was observed in group 3 and 4 mice, a degenerative area including a considerable amount of immune cell inf iltrations and f ibroblastic proliferations were also found (Fig. 1) 
Discussion
The evaluation of chemosensitivity using a xenografted tumor is based on the premise that the transplanted tumor cells retain their original characteristics in the transplanted site. In the SRC assay, the fundamental question which still remains is whether or not the host immune reaction against grafted tumor can influence the results. Since the host cells occupied only 15-20% of the total grafted volume, Aamdal et al. (1984) concluded that the influence of mouse cell infil-tration on the growth of grafted tumor was slight and that it is unnecessary to use athymic mice. In the previous work (Ushi jima, 1989), however, a significant host immune cell reaction against the grafted rat ovarian cancer tissue was observed, and the host cell infiltration could modify the size of grafted tumor and occasionally brought a complete rejection of the grafts.
Although sufficient immunosuppressive effects of CsA were observed in this study, unexpected toxicity was also experienced when an anticancer agent was concomitantly used. There are some explanations for the enhanced cytotoxic effects of CsA : i) it decreases the hepatic drug metabolizing enzyme activity (Edelstein et al. 1983) ; ii) CsA itself is cytotoxic and nephrotoxic, and it can induce a focal necrosis in the mice tubular cell of the kidney (Ushijima, 1989) ; and finally, iii) CsA is a chemosensitizer as a calcium channel blocker (Osieka et al. 1986) . In this content, a remarkable cytotoxc effects of concomitant use of CsA and an anticancer agent was noted. When CsA was combined with etoposide, most of the mice could not tolerate against the toxicity.
Hence, these results suggest that CsA treatment should be ceased before the initiation of experimental chemotherapy.
This study dose not yield any conclusive results of the immunosuppressive effect of MZB monotreatment on the experimental SRC assay system. However, the immunosuppressive effect of 3 days of applications of 200 mg/ kg of MZB following 3 days of CsA treatments were comparable to that of 7 days CsA monotreatment.
Although the optimal method to avoid immunological interference in the SRC assay remains to be resolved, the sequential treatment of CsA and MZB seems to be feasible without modification of cytotoxic effects of anticancer agents.
